Lumexa Imaging Holdings 2026 Q3 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- Q3 consolidated revenue was $272 million, up 5% year over year; system-wide outpatient revenue grew 7.7%.
- System-wide total volume grew 4.9%, and advanced modality volume grew 8.1% system-wide and 7.9% on a consolidated basis.
- Advanced modalities reached a record 38.2% of system-wide volume, 145 basis points above the prior-year period; Medjet grew 19.5% year over year.
- Adjusted EBITDA was $62.6 million, compared with $59.1 million a year ago, and grew 11% sequentially; adjusted EBITDA margin was 23.0%, up from 22.8% in Q3 '25.
- Net income was $7.2 million, compared with a net loss of $3.5 million in Q3 of '25; GAAP EPS was $0.07 per share and adjusted EPS was $0.26 per share.
- Operating cash flow was $34.8 million, and free cash flow was $20.6 million, compared with negative $1.8 million in Q3 '25.
- The company ended the quarter with $90 million in cash and cash equivalents; net leverage was 3.5 times as of September 30th, compared with 5.6 times a year ago.
- Lumexa expanded its joint venture with Advocate Health into Illinois and said it now has 10 health system joint ventures across its enterprise.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
A reminder, today's program is being recorded. Now I'd like to introduce your host for today's program, Sue Dooley, Head of Investor Relations.
Please go ahead. Thank you, and hello, everyone.
We appreciate you joining us today. Leading today's call are our Chief Executive Officer, Caitlin Zulla, and Tony Martin, our Chief Financial Officer. Before we begin, I want to note that today's discussion will include forward-looking statements, including statements regarding our 2026 guidance, expected operating performance, growth initiatives, reimbursement assumptions, capital expenditures, and other future events. These statements reflect our current expectations and assumptions that are subject to risks and uncertainties that could cause actual results to differ materially. Please refer to forward-looking statements and risk factors described in today's earnings release and our most recent SEC filings for additional information regarding those risks and uncertainties. We undertake no obligation to update those statements. We will also discuss certain non-GAAP financial measures. Definitions and reconciliations to the most directly comparable GAAP measures are included in today's earnings release.
With that, I'll now turn the call over to Caitlin. Caitlin, please go ahead. Thanks, Sue.
Before we begin, I would like to wish everyone a happy Radiologic Technology Week and say a huge thank you to this valued part of our community, as well as to our entire team at Lumexa. To our investor audience, thank you all for joining us. It's a dynamic time to be a leader in the imaging space, and we look forward to sharing our results tonight. In Q3, we advanced our strategic priorities and moved closer to our ambition of building the premier platform for high-quality, lower-cost outpatient imaging, serving patients, physicians, and health systems. We are executing well on all of our priorities, and those efforts translated directly into favorable results this quarter, including healthy EBITDA, which grew 11% over Q2, and another quarter of strong free cash flow generation. Here are a few highlights of our Q3 performance.
We saw continued strength in our core business. We drove healthy growth in systemwide same-center volumes, sustained momentum in advanced modalities across our enterprise, continued maturation of our de novo cohorts, and made important progress expanding our health system partnerships. Advanced modalities, an important driver of profitability for us, grew to a record high 38.2% of total volume systemwide, 145 basis points higher than a year ago. PET was another particular highlight in Q3, with 19.5% year-over-year growth. Our advanced modality mix shift continues to be a cornerstone of our growth strategy, yielding higher reimbursement and margin for the business. Our 2024 and 2025 de novo cohorts continue to track in line with our expectations. We just completed another careful review, and these are layering in a healthy mix of advanced volume while making meaningful strides towards our long-term growth and profit expansion objectives.
We achieved another significant milestone for our JV strategy, an expanded joint venture with our existing partner, Advocate Health, to advance our enterprise into Illinois, a new state for Lumexa Imaging. We are excited to grow alongside this prestigious health system partner and are now fortunate to count 10 health system joint ventures across our enterprise. We are maturing our joint venture pipeline, with discussions proceeding and prospective partners engaging actively around our offering, supported by valuable references from existing JV partners. We look forward to sharing more as these discussions progress. In early November, we are opening three new de novo centers in Texas, South Carolina, and North Carolina. These openings reflect our disciplined approach to expanding in attractive markets, building greater density across our network, and extending our runway for long-term sustainable growth.
With these centers, we will have five de novo openings under our belt for the year, with a clear line of sight into completing our goal of eight to 10 de novo center openings in 2026. We are also well underway with our plans for new 2027 center openings. These highlights represent progress across our key growth initiatives. They are fueling strong, durable cash generation while reinforcing our confidence in delivering on our full-year commitments, including the updated guidance we are providing tonight. Tony will speak to this more in a moment. Our Q3 achievements demonstrate effective execution, which strengthens the foundation of our long-term growth. As we have seen with ambulatory surgery, we believe shifting care to high-quality, lower-cost outpatient settings can improve access and create significant value across healthcare.
We believe a substantial opportunity lies ahead in imaging, and Lumexa is well-positioned to help lead that shift by expanding our network of wholly owned imaging centers while also partnering with health systems to expand access, accelerate diagnosis, and grow their outpatient presence while delivering better value for patients. I am proud of the progress our team is making and the energy they bring to their work at Lumexa every day. I would like to take a moment to talk about the market opportunity we are addressing. CMS has now formalized its 2027 Hospital Outpatient Prospective Payment System rule on site neutrality. The landmark site-neutral provision will reduce the reimbursement advantage associated with hospital outpatient departments and further strengthen the rationale for health systems to grow lower-cost, freestanding imaging capacity. We believe the site-neutral rule meaningfully expands our addressable market.
We are now targeting hospital outpatient imaging centers, a $44 billion incremental opportunity that builds on our existing $33 billion market for IDTF, bringing our total addressable market to roughly $77 billion. We view imaging as a critical front door to diagnosis, treatment, and specialty care. Health systems increasingly recognize the importance of that connection, and Lumexa is built to help them strengthen it. Our value extends beyond operating imaging centers. We help our partners expand access, keep patients connected to their care networks, and improve financial performance. Our model enables health systems to scale strategically and participate in outpatient imaging growth through a lower-cost operating structure that does not depend on hospital-based reimbursement premiums. We bring the operating expertise, technology, patient access capabilities, and disciplined capital deployment needed to grow and build these networks.
We see the movement towards site-neutral reimbursement as a tailwind that would unfold over years, not quarters. Our broader growth opportunity is supported by durable demand drivers across our imaging network, an aging population with increasingly complex conditions, new treatments that require advanced imaging, and expanding opportunities for early detection and screening. Additionally, CMS has issued its final 2027 Medicare Physician Fee Schedule. Medicare fee-for-service and Medicare Advantage together account for about 20% of our revenue, a small part of our overall business. We are still completing our analysis, but our preliminary assessment is that Medicare reimbursement will come in modestly below our longstanding rate assumptions, which call for approximately flat year-over-year government reimbursement rates and a 1% increase in commercial payer rates. Commercial payers represent the majority of our revenue, and those contracts renew on staggered schedules.
With nearly all of our 2027 commercial negotiations complete, we have good visibility into next year's rates. Taken together, we expect the final rule to have a limited impact on our overall 2027 reimbursement outlook. Our value proposition resonates strongly with patients, providers, health systems, and payers. Whether through our wholly owned or JV centers, we are successfully delivering high-quality imaging in more convenient settings on a timelier basis and at a lower cost than hospital outpatient departments. Across our network of centers, patients love the care they receive, which is reflected in our net promoter scores that consistently exceed 90. The market in front of us is promising and vast. Our growth priorities are clear: drive same-center growth, expand our advanced imaging mix, open and ramp new centers, scale strategic service lines, and enter attractive markets through disciplined, capital-efficient partnerships. Volume, rate, and mix underpin this strategy.
With substantial fixed costs already supported by our existing centers, additional volume, stronger reimbursement, and modality mix can generate attractive incremental margins. This operating leverage allows us to grow earnings faster than revenue as we put more patients through our established network. Let me share how we're putting these priorities into action. Our operations and commercial teams are partnering with clinical leaders to implement impactful programs to enhance care and drive engagement across our entire network of centers. Especially during the typical seasonality related to deductible resets, we are leaning in to optimize for and serve patients. For Breast Cancer Awareness Month, we partnered with Levine Cancer Institute and the Atrium Health Foundation on Project PINK, providing free screening mammograms and follow-up care to uninsured and underinsured women in the Charlotte area, bringing early detection to patients and communities where need is highest.
We continue with our lung cancer screening initiative, building patient engagement around one of the most impactful screening opportunities in our patient population. Targeted clinical outreach efforts like this remain a strength for our company. I would like to spend a moment on technology, a key driver of clinical and operational excellence at Lumexa and a differentiator as we partner with leading health systems and physician groups. First, I am thrilled to share that Dr. Aice Piros is joining Lumexa as our new Chief Clinical AI Officer, a prominent diagnostic radiologist and clinical information specialist widely recognized for his pioneering research at the intersection of medical imaging and AI.
In his new role, Dr. Piros will partner with our Chief Technology Officer and Chief Medical Officer to focus on transforming the radiologist experience and improving patient outcomes, bridging clinical practice with cutting-edge technology to drive our AI strategy, optimizing clinician workflows while producing faster, more accurate results for patients. We are advancing Lumexa Connect, our capital-light, best-of-breed technology platform built on an ecosystem of leading technologies. It lets us rapidly adopt innovation as the landscape evolves while supporting new centers, growing joint venture partnerships, and increasing volumes across advanced imaging modalities. Lumexa Connect is already delivering results. FastScan, now deployed across the majority of our enterprise, shortens MRI acquisition times by up to 40% and expands capacity across our fleet. Virtual MRI provides technologist support, staffing flexibility, and operational consistency. 100% of our telerad radiologists now use AI-enabled reporting tools.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
12 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
